




RealRate

PHARMACEUTICAL 2024

Traverse Therapeutics Inc
Rank 175 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Traverse Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Traverse Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 27% points below the market average of 213%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	616,775	Assets	788,913
Cost of Goods Sold	11,450	Liabilities	588,103
Intangible Assets	104,443	Expenses	533,599
Liabilities, Current	177,908	Revenues	145,238
Liabilities, Non-Current	32,932	Stockholders Equity	200,810
Other Assets	60,216	Net Income	-111,399
Other Compr. Net Income	1,451	Comprehensive Net Income	-110,674
Other Expenses	11,617	BaseVar	1,167,133
Other Liabilities	377,263	ECR before LimitedLiability	48%
Other Net Income	276,962	Economic Capital Ratio	186%
Other Revenues	145,238		
Property and Equipment	7,479		
Research and Development	244,990		
Selling, General and Administrative Expense	265,542		